News
The latest news from across neurorehabilitation.
News30 OctHere we reveal the 13 winners of the inaugural Awards, which celebrate excellence across the field of neuro-rehab
News26 OctA leading brain injury expert has called for reforms to the legal definition of death in the US to align the neurological criteria with wider medical standards.
News24 OctACG named as care partner for the patient support service, which works with patients and families in hospital settings
News20 Oct
Financial compensation is intended to help brain injury survivors manage their condition for the rest of their lives. But what happens when the money is lost through mismanagement, fraud or exploitation?
NR Times spoke to Liesel Annible - a forensic director at accountancy, financial and business advisory firm Armstrong Watson, to find out more about the financial investigation process.
News20 OctThe latest shortlist in the NR Times Awards has been unveiled, ahead of the awards ceremony next week
News19 OctThe number of people with neurological disorders globally is on track to double by 2050, new data suggests.
Neurological conditions are currently the second highest cause of death and the leading cause of disability worldwide and a new Global Burden of Disease (GBD) study suggests their impact could accelerate further in coming decades.
News18 OctThe ten finalists have been announced ahead of next week's awards ceremony
News17 OctA device which harnesses augmented reality (AR) to address gait and balance motor issues in Parkinson’s patients could be expanded to also help stroke survivors and people living with MS; following an investment boost.
News16 OctWorld Health Organisation presents international blueprint which it hopes will impact on the lives of people with neurological disorders.
The World Health Organisation (WHO) has called for urgent action from governments and healthcare organisations around the world to help address and better manage neurological conditions.
Multiple sclerosis16 OctBy Norman Putzki (MD PhD), global head development neuroscience and gene therapy at Novartis.
Over the last 30 years, remarkable progress has been made in the advancement of treating multiple sclerosis (MS), a potentially disabling disease that is most likely a consequence of complex autoimmune dysfunctions in the periphery ultimately leading to demyelination in the central nervous system (CNS).
Since 1993, a series of insights has led to greater understanding of the biological mechanisms and triggers driving the inflammatory attacks on the CNS.
These translational insights have also driven the development of newer and more effective treatments in MS.
